SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2024 Annual Meeting of Stockholders on Wednesday, May 29, 2024, at 9:00 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast.

旧金山--（商业新闻短讯）--Vir Biotechnology，Inc.（纳斯达克：Vir）今天提醒股东，它将于2024年5月29日星期三上午9:00 PT举行2024年股东年会。年会将仅通过现场音频网络广播以虚拟形式举行。

Vir Biotechnology’s stockholders of record at the close of business on April 1, 2024, the record date for the Annual Meeting, can attend and vote at the Annual Meeting by accessing the meeting center at www.virtualshareholdermeeting.com/VIR2024 and entering the control number on the proxy card or Notice of Internet Availability of Proxy Materials previously received.

在2024年4月1日（年度会议的记录日期）营业结束时，Vir Biotechnology的登记股东可以通过访问www.virtualshareholdermeeting.com/VIR2024上的会议中心并在代理卡上输入控制号码或之前收到的代理材料的互联网可用性通知来参加年度会议并在会议上投票。

Instructions on how to connect to the Annual Meeting and participate via the Internet are also posted at www.virtualshareholdermeeting.com/VIR2024. Online access to the Annual Meeting will begin at 8:45 a.m. PT on May 29, 2024. Stockholders should allow ample time for the check-in procedures..

关于如何连接到年会并通过互联网参与的说明也发布在www.virtualshareholdermeeting.com/VIR2024上。年会的在线访问将于2024年5月29日上午8:45开始。股东应留出充足的时间办理登机手续。。

Whether or not stockholders plan to virtually attend the Annual Meeting, Vir Biotechnology urges them to vote and submit their proxy in advance of the Annual Meeting by one of the methods described in the proxy materials for the Annual Meeting.

无论股东是否计划实际参加年会，Vir Biotechnology都敦促他们在年会之前通过年会代理材料中描述的方法之一进行投票并提交代理。

About Vir Biotechnology, Inc.

关于Vir Biotechnology，Inc。

Vir Biotechnology, Inc. is an immunology company focused on powering the immune system to transform lives by treating and preventing infectious diseases and other serious conditions, including viral-associated diseases. Vir has assembled two technology platforms that are designed to modulate the immune system by exploiting critical observations of natural immune processes.

Vir Biotechnology，Inc.是一家免疫学公司，专注于通过治疗和预防传染病和其他严重疾病（包括病毒相关疾病），为免疫系统提供动力，以改变生活。Vir已经组装了两个技术平台，旨在通过利用对自然免疫过程的关键观察来调节免疫系统。

Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website..

其目前的临床开发流程包括针对三角洲肝炎病毒、乙型肝炎病毒和人类免疫缺陷病毒的候选产品。Vir有几个临床前候选药物，包括针对甲型和乙型流感，新型冠状病毒，RSV/MPV和HPV的候选药物。Vir定期在其网站上发布对投资者可能很重要的信息。。